Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22479596 | 0.83 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL21394860 | 0.83 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2306577 | 0.79 | MAPT (0.55) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2890719 | 0.78 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL21394858 | 0.78 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL286957 | 0.77 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL31728945 | 0.77 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2831032 | 0.74 | NPC1 (0.51) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL21597797 | 0.73 | KDM4E (0.47) | ALDH1A1L3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2827379 | 0.73 | BAZ2B (0.71) | ALDH1A1L3MBTL1RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506202-A | mGluR5 modulators I | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | claimed |
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | ALDH1A1 4350/4885L3MBTL1 4675/4885MAPT 750/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | ALDH1A1 293/4885L3MBTL1 3090/4885MAPT 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.